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BSC1 inhibition complements effects of vasopressin V2 recep-
tor antagonist on hyponatremia in SIADH rats.
Background. Severe hyponatremia is most frequently caused
by the syndrome of inappropriate secretion of antidiuretic hor-
mone (SIADH). Although the expressional alteration of the
kidney-specific apical water channel, aquaporin 2 (AQP2), in
the collecting duct has been demonstrated to be involved in the
development of hyponatremia and the subsequent physiologic
reaction that is resistant to arginine vasopressin (AVP; vaso-
pressin escape) in SIADH, the complete pathogenesis of and
the appropriate medical treatment for hyponatremia have yet
to be elucidated.
Methods. Hyponatremia was induced in male Sprague-
Dawley rats by water loading and subcutaneous infusion of
1-deamino-8-D-arginine vasopressin (dDAVP). For the treat-
ment, a selective AVP V2 receptor antagonist (OPC-31260)
and/or a loop diuretic (furosemide) were administered orally.
Protein expression of AQP2 and rat bumetanide-sensitive co-
transporter (rBSC1) was examined by Western blotting during
the hyponatremia and the subsequent treatment.
Results. We noted a markedly high expression of rBSC1 dur-
ing the development of hyponatremia, and a relatively low ex-
pression during vasopressin escape. OPC-31260 administration
elevated serum sodium level in a dose-dependent manner. The
therapeutic effect, however, declined with increasing number
of treatment days, and doses higher than 15 mg/kg/day induced
severe toxicity. The physiologic parameters and the alterations
of AQP2 and rBSC1 expression during the treatment demon-
strated reactions that were completely opposite to those of va-
sopressin escape. Combination of a furosemide (100 mg/kg/day)
and a low dose of OPC-31260 (5 mg/kg/day) additively elevated
serum sodium level and sustained the elevated serum sodium
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level by significantly reducing sodium accumulation in the renal
medulla.
Conclusion. AVP-induced alterations of rBSC1 expression,
as well as those of AQP2, are involved in the pathogenesis
of SIADH. The pharmacologic blockade of AVP stimulus in
SIADH limits its therapeutic efficacy by discontinuing the va-
sopressin escape, and the selective inhibition of rBSC1 comple-
ments this limitation.
Hyponatremia is the most common disorder of body
fluid and electrolyte balance encountered in clinical
practice [1]. Severe hyponatremia is most frequently
caused by the syndrome of inappropriate secretion of
antidiuretic hormone (SIADH) [2]. SIADH is a condi-
tion in which plasma arginine vasopressin (AVP) level
is not appropriately suppressed despite hypoosmolality
[3]. Sustained water intake due to chronic exposure to
AVP can result in net water retention and the devel-
opment of hyponatremia [4]. Recently, the involvement
of the apical collecting duct water channel, aquaporin
2 (AQP2), has been demonstrated in the pathogene-
sis of SIADH [5–7]. AVP stimulates the transcription
of the AQP2 gene by activating adenosine 3′, 5′-cyclic
monophosphate (cAMP) responsive element (CRE) up-
stream of the AQP2 gene [8]. For renal water reab-
sorption through AQP2, sodium reabsorption is required
in advance to induce an osmotic gradient in the renal
medulla. A kidney-specific sodium cotransporter (BSC1;
bumetanide-sensitive cotransporter) in the thick ascend-
ing limb of Henle (TAL) supplies critical sodium to
the medullary interstitium for concentrating urine [9,
10]. The final urinary concentration for the mainte-
nance of body fluid has been determined by harmo-
nious expression of these proteins and urea transporters
in the collecting duct [11–16]. We have demonstrated
that BSC1 expression leading to urinary concentration is
regulated by at least two different mechanisms, namely,
AVP-dependent and -independent mechanisms, whereas
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AQP2 is highly dependent on AVP stimulus [17]. Since
SIADH is a water retention disorder and is character-
ized by inappropriate urinary concentration [18], BSC1
expression, as well as AQP2 expression, was expected to
be enhanced after 1-deamino-8-D-arginine vasopressin
(dDAVP) infusion. Therefore, the first purpose of our
study was to investigate whether or not changes in
BSC1 expression are attributable to the development of
SIADH.
The most rational therapeutic strategy for SIADH is
to exclude the underlying causes of excessive AVP stim-
uli. In most cases, however, this is difficult, and fluid re-
striction for ameliorating excessive water retention is the
present mainstay of the treatment of SIADH patients.
Several drugs, such as ethanol, diphenylhydantoin, and
opiates, have been noted to decrease AVP secretion in
some cases [19], whereas demeclocycline and lithium car-
bonate have been advocated to reduce the renal action
of AVP [20, 21]. However, because of their erratic and
unpredictable responses or significant side effects, they
are deemed impractical for clinical use [22, 23]. A potent
peptide AVP V2 receptor antagonist was developed by
Manning and Sawyer [24]; however, its therapeutic use-
fulness was limited because of its low oral bioavailabil-
ity and partial agonist activity. Recently, Yamamura et al
developed an orally effective and highly selective non-
peptide AVP V2 receptor antagonist, OPC-31260 [25].
It has been demonstrated to increase renal solute-free
water excretion in humans [26], and early experience in
SIADH patients has indicated substantial improvement
of hyponatremia [27]. On the other hand, furosemide, a
BSC1 inhibitor with compensatory salt intake, has been
reported to be successfully used in SIADH patients [28],
although its effects have not yet been demonstrated in
animal models of SIADH. The second purpose of our
study was to evaluate the pharmacologic therapy for
SIADH based on the results of BSC1 expression in our
present study. To this end, we administered OPC-31260,
furosemide, or a combination of both to SIADH rats and
investigated their effects on various physiologic param-
eters. Together with the present findings of AQP2 and
BSC1 expression during the development and treatment
of SIADH, our present study has provided novel insights
into the pathophysiology and pharmacologic therapy of
SIADH.
METHODS
Experimental animals
Male Sprague-Dawley rats weighing 200 g were used.
They were housed in individual cages in a humidity-
and temperature-controlled room with a 12-12-hour
light-dark cycle. All experimental protocols described
in the present study were approved by the Ethics Re-
view Committee for Animal Experimentation of Tohoku
University.
Animal preparation
A slightly modified version of the SIADH model orig-
inally developed by Verbalis [18] was used as described
previously [5, 7, 29] (Fig. 1). Rats were acclimated for four
days to a gelled-agar diet composed of 67% water, 27%
finely powdered rat chow, 4.7% glucose, and 1.3% agar,
in which 0.084% sodium and 0.27% potassium were con-
tained. The agar was melted in boiling water and poured
into a mold, and then the powdered chow and glucose
were added and stirred to an even consistency. The diet
was then chilled at 4◦C to form a firm, gelatin-like state.
The rats received 90 g of this preparation each day. The
diet forced the rats to consume a greater volume of water
to take the enough calories. After four days of the ac-
climatization period with water loading, the SIADH rats
underwent osmotic minipump (model 2002; Alza Cor-
poration, Palo Alto, CA, USA) implantation. Osmotic
minipumps containing dDAVP (Kyowa Hakko, Tokyo,
Japan) dissolved in 0.15 mol/L NaCl to make a concentra-
tion of 10 lg/mL were implanted subcutaneously on the
back under ether anesthesia, and dDAVP was infused at
a rate of 5 ng/h. After recovery, the animals were placed
in cages with free access to the gelled-agar diet for the
additional days. All the rats were given the same amount
of the gelled-agar diet over the entire course of the exper-
iment. They were placed individually in metabolic cages
to facilitate urine collection and recording of individual
food and water intake. Twenty-four–hour urine collection
was conducted daily in order to measure urine volume,
urine osmolality, and sodium and potassium levels. Body
weight and water and food intake were also measured
daily. Net daily sodium and potassium balance was calcu-
lated as the difference between dietary intake and urine
output. Fecal electrolyte loss was assumed to be small and
constant. We sampled 0.3 mL of blood from tail veins to
determine serum sodium levels and plasma osmolality ev-
ery two days. For the removal of kidneys, 4 mL of trunk
blood was collected by bleeding the animals to death un-
der ether anesthesia. Three series of experiments were
performed (Fig. 1).
Series 1. Changes in the physiologic parameters of the
SIADH rats were closely examined for 14 days to eval-
uate the appropriate rat model for SIADH (Fig. 1A).
To further confirm the propriety of this model, changes
in AQP2 protein expression were analyzed. Rat BSC1
(rBSC1) protein expression was also examined to inves-
tigate the involvement of altered rBSC1 expression in the
development of SIADH. SIADH rats were sacrificed at
different time points, specifically, on days two and seven
after the dDAVP infusion, whereas control rats without
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Fig. 1. Diagram of experimental format.
Sprague-Dawley rats were water-loaded from
day 4 and subcutaneously infused with
dDAVP (infusion rate: 5 ng/hr) from day 0.
(A) Series 1. Kidneys from SIADH rats were
removed on days 2 and 7 after dDAVP infu-
sion, whereas kidneys from control rats were
removed after an additional 7 days of water
loading. (B) Series 2. Rats were administered
OPC-31260 and/or furosemide from day 7.
Kidneys from rats of group 1 (5 mg/kg OPC-
31260) were removed 3 hours after the initial
administration and at the end of observation
period, while kidneys from rats of group 7 (100
mg/kg furosemide), 8 (5 mg/kg OPC-31260
and 30 mg/kg furosemide), and 9 (5 mg/kg
OPC-31260 and 100 mg/kg furosemide) were
removed at the end of the observation period.
(C) Series 3. Rats were administered 5 mg/kg
OPC-31260 or 100 mg/kg furosemide from
day 7. Kidneys from the rats were removed
before the initial administration and 3 hours,
24 hours, 3 days, and 7 days after the initial ad-
ministration. Six rats were used in each con-
dition. Abbreviations are: OPC, OPC-31260;
FUR, furosemide; dDAVP, 1-deamino-8-D-
arginine vasopressin.
the dDAVP infusion were sacrificed after an additional
seven days of water loading. The kidneys were rapidly
removed and used in experiments for immunoblotting
and electrolyte measurement.
Series 2. Based on the finding in series 1 that the hy-
ponatremic condition was stabilized from day five of
the dDAVP infusion, therapeutic interventions were de-
signed (Fig. 1B). According to the groups listed below
(N = 6 per group), OPC-31260, furosemide, or a combi-
nation of both was administered to the SIADH rats: (1)
Administration of OPC-31260. In group 1, the SIADH
model rats were administered 5 mg/kg OPC-31260
(Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan).
In group 2, 10 mg/kg. In group 3, 15 mg/kg. In group
4, 20 mg/kg. In group 5, 30 mg/kg. (2) Administration
of furosemide. In group 6, the SIADH rats were admin-
istered 30 mg/kg furosemide (Wako Pure Chemical In-
dustries, Ltd., Osaka, Japan). In group 7, 100 mg/kg. (3)
Combined administration of OPC-31260 and furosemide.
In group 8, the SIADH rats were administered 5 mg/kg
OPC-31260 and 30 mg/kg furosemide in combination. In
group 9, 5 mg/kg OPC-31260 and 100 mg/kg furosemide
were administered. All the SIADH rat groups were sub-
jected to oral administration of the drugs via a gastric
tube once a day from days seven to 13 at a dose of 2.0
mL/kg. The drugs were suspended in water containing
1% methylcellulose (Wako Pure Chemicals). We sampled
0.3 mL of blood from the tail veins to determine serum
sodium level every day during the treatment. Serum cre-
atinine and urea concentrations were determined before
and after the entire course of treatment. Both kidneys
from the rats of groups 1 (5 mg/kg OPC-31260) were
rapidly removed three hours after the initial administra-
tion and at the end of observation period. Kidneys from
the rats of group 7 (100 mg/kg furosemide), 8 (5 mg/kg
OPC-31260 and 30 mg/kg furosemide), and 9 (5 mg/kg
OPC-31260 and 100 mg/kg furosemide) were removed at
the end of the observation period. These kidneys were
used for measurements of electrolytes and urea in the
renal medulla
Series 3. To investigate the mechanisms underlying the
therapeutic limitations of OPC-31260 as demonstrated
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in series 2, we closely examined the changes in AQP2
and rBSC1 protein expression during OPC-31260 or
furosemide treatment (Fig. 1C). Kidney tissue was sam-
pled before the initial administration and three hours, 24
hours, three days, and seven days after the initial admin-
istration of 5 mg/kg OPC-31260 or 100 mg/kg furosemide,
and was used in immunoblotting experiments.
Immunoblotting
Immunoblotting using a specific antibody against
AQP2 or rBSC1 was performed as previously described
[17, 30, 31]. Briefly, after dividing the harvested kid-
neys into three parts—cortex, outer medulla, and inner
medulla—the renal outer medulla and the inner medulla
were separately homogenized in 2 mL of phosphate-
buffered saline (PBS), 1% Triton, 1% deoxycholate,
0.1% sodium dodecyl sulfate (SDS), and 0.1 mmol/L
phenylmethylsulfonyl fluoride (PMSF) for protein ex-
traction. Twenty-five lg of protein was loaded in each lane
for Laemmli’s SDS-polyacrylamide gel electrophore-
sis (PAGE) (8 or 12.5%), and then transferred to a
polyvinylidene difluoride membrane. The membrane was
blocked for one hour and exposed to antibody diluted
with 2.5% milk powder/TBST (10 mmol/L Tris-HCl, pH
8.5, 150 mmol/L NaCl, and 0.1% Tween 20) overnight at
4◦C, and then to a second antibody (peroxidase linked
antirabbit IgG) for one hour at room temperature. Af-
ter washing, antigen-antibody complexes were visualized
with a chemiluminescence system (ECL Plus; Amersham
Bioscience, Piscataway, NJ, USA).
Measurements of electrolytes and urea in renal medulla
Electrolyte and urea concentrations in the renal
medulla were determined according to previous studies
in which solute accumulation in the renal medulla was
measured [17, 30]. Briefly, the renal inner medulla was
separated, put inside a microcentrifuge tube, and quickly
weighed. The tube was then immersed in an 80◦C wa-
ter bath for 60 minutes to inactivate the enzymes. The
tube was dried in an oven set at 80◦C for 48 hours and
reweighed after the tissue had attained complete dryness.
Distilled water was then added and the tube was placed
in an oven set at 80◦C for two hours to facilitate extrac-
tion of ions and urea into the water. The tube was cooled
to 18◦C and reweighed to determine the volume of the
added water. Then, the supernatant was used for elec-
trolyte and chemical analysis. Sodium, potassium, and
urea concentrations were expressed per gram of tissue
weight.
Other measurements and statistical analyses
Serum and urinary sodium and potassium levels were
measured by an autoanalyzer (M-644, Bayer Co., East
Walpole, MA, USA). Serum urea and creatinine levels
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Fig. 2. Serum sodium levels and AQP2 protein expression in SIADH
rats. (A) Serum sodium level during the 14-day subcutaneous dDAVP
infusion. Data represent the mean ± SEM of 6 determinations in each
condition. (B) AQP2 protein expression by immunoblotting. Twenty-
five lg of protein extracted from the renal inner medulla was loaded in
each lane. Rats without dDAVP infusion (control), and those on days 2
and 7 of dDAVP infusion, were examined.
and tissue urea level were measured by a chemical auto-
analyzer (DRI-CHEM 3500V, Fuji Film, Tokyo, Japan).
Plasma and urinary osmolality was determined with an
osmometer (model 3D2; Advanced Instruments, Need-
ham Heights, MA, USA). The results are expressed
as mean ± SEM. Statistical comparisons in all the
physiologic and laboratory data were made among the
treatment groups using analysis of variance (ANOVA)
followed by Dunnett’s test or Student t test for individual
comparisons. A P value < 0.05 was considered significant.
RESULTS
Changes in serum sodium level and AQP2
protein expression
In the SIADH rats, serum sodium levels were markedly
decreased to nearly 100 mmol/L on day two of the dDAVP
infusion, indicating the onset of hyponatremia. Although
slight elevation was noted from days four to five, contin-
uous hyponatremia at less than 110 mmol/L was main-
tained thereafter (Fig. 2A). Plasma hypoosmolality was
also maintained (data not shown). Then, AQP2 protein
expression was examined on days two and seven, which
are the onset of hyponatremia and the stabilized phase
of continuous hyponatremia, respectively (Fig. 2B).
Western blots of AQP2 demonstrated highly intense
bands on day two, followed by a slight decline of the
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Fig. 3. rBSC1 protein expression. (A) Signal bands of immunoblotting.
Twenty-five lg of protein extracted from the renal outer medulla was
loaded in each lane. Rats without dDAVP infusion (control), and those
on days 2 and 7 of dDAVP infusion, were examined. (B) Level of protein
expression was determined from the signal density. ∗P < 0.05 compared
to rats without dDAVP infusion (control), #P < 0.05 compared to rats on
day 2 of dDAVP infusion. Data are mean ± SEM of 6 determinations in
each condition. Differences among the treatment groups were analyzed
by ANOVA, followed by Dunnett’s test or Student t test.
band intensity on day seven, although it was still stronger
than that of control (Fig. 2B). Densitometric analysis us-
ing 42 kD bands (six determinations for each condition)
confirmed a statistically significant decrease in band in-
tensity from days two to seven and a remaining intensity
on day seven that was stronger than that of the control
(data not shown). These alterations in AQP2 expression
are consistent with previous findings of enhanced AQP2
expression at the acute phase of SIADH, followed by the
AVP escape phenomenon [5–7].
Changes in rBSC1 protein expression level
rBSC1 protein expression before and after the dDAVP
infusion is demonstrated in Figure 3. A marked increase
in expression was noted again on day two (Fig. 3A). In
the same way as AQP2 expression, the expression was
decreased on day seven, although it was still significantly
higher than that of the control (Fig. 3A). Statistically sig-
nificant difference between control rats and SIADH rats
and between day two and day seven was confirmed by
measuring signal density (Fig. 3B).
Effects of therapeutic intervention on serum sodium
Administration of OPC-31260. Based on the findings
of AQP2 and rBSC1 expression, we designed the thera-
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Fig. 4. Serum sodium levels in SIADH rats during treatment. (A)
OPC-31260 alone. Open circles, group 1, OPC-31260 5 mg/kg; open
squares, group 2, OPC-31260 10 mg/kg; filled circles, group 3, OPC-
31260 15 mg/kg; filled squares, group 4, OPC-31260 20 mg/kg; filled
triangles, group 5, OPC-31260 30 mg/kg. (B) Furosemide alone. Open
circles, group 6, furosemide 30 mg/kg; open squares, group 7, furosemide
100 mg/kg. (C) Combination of OPC-31260 and furosemide. Open cir-
cles, group 1, OPC-31260 5 mg/kg; open squares, group 8, OPC-31260
5 mg/kg and furosemide 30 mg/kg; filled circles, group 9, OPC-31260 5
mg/kg and furosemide 100 mg/kg. Data represent the mean ± SEM of 6
determinations in each condition. Abbreviations are: OPC, OPC-31260;
FUR, furosemide.
peutic intervention. As the expression of these two pro-
teins is promoted by AVP through V2 receptor mediated
pathways [11, 12, 17], OPC-31260, an AVP V2 receptor
antagonist, was chosen for the treatment of the SIADH
rats (Fig. 4A). Oral administration of OPC-31260 was
started on day seven when the physiologic reactions to the
dDAVP infusion were stabilized. Figure 4A demonstrates
the OPC-31260 dose-dependent effects of serum sodium
levels. OPC-31260 doses higher than 10 mg/kg abruptly
elevated serum sodium levels to above 130 mEq/L in one
day, followed by a gradual elevation to the maximum. All
the rats administered 30 mg/kg OPC-31260 and half of
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the rats administered 15 or 20 mg/kg OPC-31260 expired
during the course of treatment. The surviving rats that
were administered 15 or 20 mg/kg OPC-31260 showed
such abnormal behavior as agitation, hypersensitivity, or
disorientation. Although all rats that were administered
10 mg/kg survived the observation period, one of them
showed the abnormal behavior described above. In rats
administered 5 mg/kg OPC-31260, the elevation of serum
sodium was slower and smaller than that in rats admin-
istered a higher dose of OPC-31260, and no abnormal
behavior was noted.
Administration of furosemide. Based on the present
findings of increased rBSC1 expression in the SIADH
rats, the effects of the functional inhibitor of BSC1,
furosemide, were examined, as shown in Figure 4B. The
administration of furosemide also elevated serum sodium
levels in a dose-dependent manner, but had none of the
significant side effects observed in rats administered a
high dose of OPC-31260. The maximum serum sodium
level, however, was below 125 mEq/L, even when a high
dose of furosemide (100 mg/kg) was administered. Ad-
ministration of low-dose furosemide (3 mg/kg, 10 mg/kg)
did not show any therapeutic effects.
When OPC-31260 and furosemide were compared,
it was found that 5 mg/kg OPC-31260 elevated serum
sodium level at a higher rate than 100 mg/kg furosemide
(Fig. 4A and B). This therapeutic effect of OPC-31260,
however, was gradually decreased with increasing num-
ber of treatment days (Fig. 4A), whereas furosemide
maintained the serum sodium level throughout the ob-
servation period (Fig. 4B).
Combined administration of OPC-31260 and furo-
semide. As a high dose of OPC-31260 produces se-
vere side effects and furosemide shows small but steady
therapeutic effects, we tested the effects of combination
therapy with a low dose of OPC-31260 and furosemide.
As shown in Figure 4C, when 5 mg/kg OPC-31260 was
used in combination with 30 mg/kg furosemide, a slightly
faster and greater rise of the serum sodium level than
that of the administration of 5 mg/kg OPC-31260 alone
was noted. The therapeutic effects, however, were grad-
ually decreased from day 10 as in rats administered
OPC-31260 alone. In contrast, when 5 mg/kg OPC-31260
was used in combination with 100 mg/kg furosemide,
the serum sodium concentration was further elevated
than with that of 30 mg/kg furosemide, and the ef-
fects were well maintained throughout the observation
period.
Electrolyte and urea accumulation in renal medulla of
rats with OPC-31260 and/or furosemide treatment
In our therapeutic intervention, the combined treat-
ment with OPC-31260 and furosemide showed the best
therapeutic effect of increasing serum sodium level with-
out producing any side effects. Thus, we investigated the
mechanisms of the effects of furosemide by examining the
accumulated levels of electrolytes and urea in the renal
medulla. First, we examined the alterations of these pa-
rameters during the onset of SIADH and treatments by
5 mg/kg OPC-31260 (group 1) or 100 mg/kg furosemide
(group 7), as shown in Figure 5. The infusion of dDAVP
for two days markedly increased both sodium and urea
accumulation (Fig. 5A and B). Although OPC-31260
significantly decreased sodium and urea accumulation
transiently three hours after the initial administration, it
returned at the end of observation period to the
level before treatment (Fig. 5A and B). On the other
hand, furosemide significantly lowered the accumulated
sodium even at the end of observation period (Fig. 5A).
Urea accumulation also tended to be decreased (P =0.07)
by this treatment (Fig. 5B). Second, these parameters
were compared among the three groups, namely 5 mg/kg
OPC-31260 alone, 5 mg/kg OPC-31260 and 30 mg/kg
furosemide, and 5 mg/kg OPC-31260 and 100 mg/kg
furosemide (Fig. 6). The accumulated level of sodium in
the renal inner medulla was significantly decreased in the
group administered a high dose of furosemide (Fig. 6A),
in which the large additive effects of furosemide on the
serum sodium level were constantly noted (Fig. 4C).
Although there was no difference in potassium accumu-
lation (Fig. 6B), sodium accumulation in the group ad-
ministered a low dose of furosemide was slightly, but not
significantly lower than that in the group administered
OPC-31260 alone (Fig. 6A), and urea accumulation was
also slightly, but not significantly decreased with increas-
ing dose of furosemide (Fig. 6C).
Physiologic changes throughout the observation period
The therapeutic trial of the present study confirmed the
therapeutic effects of a low dose of OPC-31260, which
were enhanced by furosemide. However, it also revealed
several problems that have to be addressed: (1) a high
dose of OPC-31260 demonstrated severe toxicity; (2)
the therapeutic effects of OPC-31260 were gradually de-
creased with increasing number of treatment days; (3)
furosemide treatment might influence total sodium bal-
ance because of its pharmacologic effect of natriuresis.
To address these problems, we closely analyzed the phys-
iologic changes in the rats throughout the experimental
period, as follows.
Changes in body weight. Figure 7 shows the changes
in body weight of all the rats except those administered
more than 20 mg/kg OPC-31260. Before the dDAVP in-
fusion, constant weight gain by natural growth was noted.
The weight gain was enhanced for two days after the sub-
cutaneous infusion of dDAVP, which coincided with the
onset of hyponatremia. A transient decrease was noted
on days two to four, when hyponatremia was slightly
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Fig. 5. Electrolyte and urea accumulation in renal medulla. Rats of control, SIADH (day 2 of dDAVP infusion, before treatment), groups 1 (5 mg/kg
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Fig. 6. Electrolyte and urea accumulation in renal medulla. Rats of groups 1 (5 mg/kg OPC-31260), 8 (5 mg/kg OPC-31260 and 30 mg/kg furosemide),
and 9 (5 mg/kg OPC-31260 and 100 mg/kg furosemide) were examined. (A) Sodium. ∗P < 0.05 compared to rats of group 1. (B) Potassium. (C)
Urea. Data represent the mean ± SEM of 6 determinations in each condition. Differences among the treatment groups were analyzed by ANOVA,
followed by Dunnett’s test or Student t test.
ameliorated (Fig. 2A). The weight gain recovered there-
after under the constant hyponatremic condition. The
body weights of the rats administered OPC-31260 are
shown in Figure 7A. Whereas the rats administered 5
mg/kg OPC-31260 continued to gain weight, those admin-
istered 10 mg/kg OPC-31260 showed a transient decrease.
On the other hand, the rats administered 15 mg/kg OPC-
31260 showed progressive weight loss, and half of them
died during the course of treatment. The rats adminis-
tered 20 or 30 mg/kg OPC-31260 showed further weight
loss (data not shown), and most of them died. The body
weight of the rats administered furosemide (Fig. 7B) or
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mean ± SEM of 6 determinations in each condition. Abbreviations are:
OPC, OPC-31260; FUR, furosemide; dDAVP, 1-deamino-8-D-arginine
vasopressin.
subjected to combination therapy (Fig. 7C) did not show
any abnormal weight loss.
Changes in urine volume, urine osmolality, and water
balance. Figures 8A and B show the time courses of urine
volume and urine osmolality, respectively. To further an-
alyze body fluid condition, water balance was determined
by subtracting urine volume from water intake, as shown
in Figure 8C. Urine volume was markedly reduced and
urine osmolality was markedly increased on day two
(Fig. 8A and B), when both AQP2 and rBSC1 were
strongly expressed (Figs. 2B and 3). The fact that urine
volume and urine osmolality gradually recovered there-
after (Fig. 8A and B) is physiologic evidence of vaso-
pressin escape; this was also supported by the decline in
AQP2 and rBSC1 protein expression (Figs. 2B and 3).
The transient increase in water balance on day one or
two (Fig. 8C) coincided with the increase in weight gain
(Fig. 7), producing dilutional hyponatremia (Fig. 2A).
These changes in urine volume, urine osmolality, and wa-
ter balance are consistent with the results of previous
studies [5, 7, 18, 29], and confirm the physiologic propri-
ety of the rats as models of SIADH.
To determine the influence of therapeutic interven-
tion on the above parameters, we continued to measure
the parameters after administration of OPC-31260 and/or
furosemide. In rats subjected to OPC-31260 administra-
tion or combination therapy, a rapid increase in urine
volume (Fig. 8A) and a corresponding decrease in urine
osmolality (Fig. 8B) were noted one day after OPC-31260
administration. These changes, however, were transient
and absent in rats administered furosemide alone. These
differences in the results of urinalysis may be related to
the different patterns of elevating serum sodium (Fig. 4)
between OPC-31260 and furosemide. In rats adminis-
tered more than 10 mg/kg OPC-31260, water balance
was decreased significantly within two days after the
administration (Fig. 8C). Although no data are shown,
all rats administered more than 20 mg/kg OPC-31260,
and half of the rats administered 15 mg/kg OPC-31260,
showed severe decreases in water balance and expired
during the observation period, indicating that a high
dose of OPC-31260 may induce marked reduction of
intake, resulting in severe dehydration and malnutri-
tion. In contrast, in rats subjected to furosemide admin-
istration or combination therapy with 5 mg/kg OPC-
31260, no changes in any of these parameters were
observed.
Changes in net sodium and potassium balance.
Furosemide causes natriuresis in normal rats with euhy-
dration [25]. This natriuretic effect of furosemide is con-
sidered to counter the therapeutic effects in the SIADH
rats. Thus, we investigated the presence or absence of in-
appropriate natriuresis induced by furosemide adminis-
tration in SIADH rats by analyzing sodium and potassium
balance (Fig. 9). Net daily sodium and potassium balance
was determined by subtracting urine output from dietary
intake. As shown in Figure 9A, a positive net sodium bal-
ance was maintained during the course of treatment in all
the treatment groups. A transient increase in the positive
net sodium balance was noted in rats administered OPC-
31260 alone or subjected to combination therapy one day
after drug administration, which might have contributed
to a rapid and large elevation of serum sodium and its
subsequent decline (Fig. 4A and C). On the other hand,
there were no significant changes in kaliuresis in all
the treatment groups (Fig. 9B). These indicate that
furosemide, as well as OPC-31260, does not have any
specific natriuretic effects on SIADH rats. The
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FUR, furosemide; dDAVP, 1-deamino-8-D-arginine vasopressin.
combination of those two drugs does not have any na-
triuretic effects either. In contrast, OPC-31260 showed
transient sodium sparing effect one day after the initial
drug administration.
Serum levels of urea, creatinine, and potassium. Serum
levels of urea, creatinine, and potassium were measured
before and after drug administration in rats that were
alive at the end of the observation period. Neither OPC-
31260 nor furosemide altered the serum levels of creati-
nine and potassium. Even in rats administered 15 mg/kg
OPC-31260, the three surviving rats showed no alteration
of these parameters. Serum urea levels, however, were
slightly but significantly (P < 0.05) elevated in rats admin-
istered OPC-31260 (from 11.1 ± 0.4 to 14.2 ± 0.7 mg/dL
and from 11.4 ± 0.5 to 14.6 ± 0.9 mg/dL in rats adminis-
tered 5 mg/kg and 10 mg/kg OPC-31260, respectively),
whereas it remained unchanged in rats administered
furosemide alone (from 11.2 ± 0.6 to 12.5 ± 0.6 mg/dL
in rats administered 100 mg/kg furosemide). This differ-
ence may also be induced by the transient decrease in
water balance (Fig. 8C) and the increase in urine volume
(Fig. 8A) one day after OPC-31260 administration.
Changes in protein expression after OPC-31260
administration
All the physiologic parameters examined indicated the
rapid appearance of the effects of OPC-31260, which sup-
ported the rapid and strong therapeutic effects on hy-
ponatremia. Such physiologic alterations, however, were
transient, and the therapeutic effects were also decreased
with increasing number of treatment days. To further in-
vestigate the mechanisms underlying these therapeutic
limitations of OPC-31260, we closely examined AQP2
and BSC1 protein expression during OPC-31260 admin-
istration (Fig. 10). Western blots demonstrated a rapid
and marked reduction of the expression of both AQP2
and rBSC1 three hours after the initial administration
of 5 mg/kg OPC-31260. The expression, however, was re-
covered 24 hours after the initial administration, followed
by further enhancement of the expression of both AQP2
and rBSC1 three and seven days after the initial admin-
istration. We confirmed the lack of alterations in these
proteins’ expression by furosemide treatment (data not
shown).
DISCUSSION
In the present study, we investigated rBSC1 expression
in rat with hyponatremia, which has been well established
as a disease model for SIADH in previous studies [5, 7, 18,
29]. To confirm the presence of reported physiologic re-
actions during the development of the disease, we closely
examined serum sodium level, AQP2 protein expression,
and the results of urinalysis. Our examinations revealed
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B
Fig. 10. Protein expression during OPC-
31260 (5 mg/kg) treatment. (A) AQP2 pro-
tein expression. Twenty-five lg of protein ex-
tracted from the renal inner medulla was
loaded in each lane. (B) rBSC1 protein ex-
pression. Twenty-five lg of protein extracted
from the renal outer medulla was loaded in
each lane. Rats before the initial administra-
tion and 3 hours, 24 hours, 3 days, and 7 days
after the initial administration were exam-
ined.
that the onset of SIADH involves a combination of ex-
cessive water intake and exogenous dDAVP infusion, as
well as the presence of vasopressin escape, in response to
continuous exposure to high levels of plasma AVP. Using
this rat model for SIADH, we observed a high rBSC1 pro-
tein expression after dDAVP infusion. Although rBSC1
expression is promoted by multiple mechanisms [17, 32,
33], AVP is one of the strong stimulators of its expression
[17], and specific conditions leading to high rBSC1 ex-
pression, such as dehydration [15, 17], heart disease [34],
and liver disease [35] were absent in the rats of the present
study. In addition, rBSC1 expression was altered consis-
tently with the alteration of AQP2 expression: (1) rBSC1
expression was markedly enhanced by dDAVP infusion,
and (2) it was markedly reduced by the administration
of an AVP V2 receptor antagonist. These results indicate
that rBSC1 expression is regulated by an AVP-mediated
mechanism in the rats of the present study. As we also
demonstrated the increased sodium and urea accumula-
tion in renal medulla leading to water reabsorption, the
high rBSC1 expression by AVP stimulus may also partic-
ipate in the development of hyponatremia in the SIADH
rats.
Serum sodium level was progressively lowered with the
elevation of urinary osmolality and the reduction of urine
volume for a period of two to three days after the start of
dDAVP infusion. Then, the decrease of serum sodium
level stopped at the lowest hyponatremia of nearly
100 mmol/L on day three, and serum sodium level was set-
tled a little higher than that from day five by reducing the
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physiologic responses to AVP stimulus. This reduction is
recognized as vasopressin escape. Recently, Saito et al
presented direct evidence of the reduced response to
AVP stimulus by showing diminished AQP2 expression
during vasopressin escape [5]. In the present study, we
found that rBSC1 expression at this stage of SIADH is
also less than that of the lowest hyponatremia on day two.
As rBSC1 expression influences the corticomedullary
osmotic gradient leading to urinary concentration [17],
this alteration of rBSC1 expression is thought to explain
the previous finding of dissipation of the osmotic gradi-
ent during vasopressin escape [36]. Vasopressin escape
is therefore considered to be induced by the decreased
expression of both AQP2 and rBSC1.
We investigated the therapeutic intervention based on
the present finding that the expressional alteration of
rBSC1 is involved in the pathogenesis of SIADH. We
started by reexamining the therapeutic effects of OPC-
31260, an AVP V2 receptor antagonist. OPC-31260 is the
first nonpeptide V2 receptor antagonist that possesses
high selectivity for the V2 receptor [25]. In the SIADH
rats, the high expression of both AQP2 and rBSC1 is
thought to be induced by AVP stimulus, as mentioned
above. Thus, OPC-31260, which blocks the effects of AVP,
may reduce the expression of these cell surface proteins,
theoretically leading to the remission of the disease. As
expected, this drug elevated serum sodium level in a dose-
dependent manner. High doses of OPC-31260 exceed-
ing 15 mg/kg, however, showed severe toxicity. Fujisawa
et al used the same drug and reported therapeutic effects
at 5 mg/kg OPC-31260 and severe toxicity at 30 mg/kg,
which was attributable to brain myelinolysis as a result of
rapid correction of hyponatremia [29], as was histopatho-
logically demonstrated by Ayus et al [37]. However, they
did not describe the effects of doses between 5 and
30 mg/kg. Our present study revealed that OPC-31260
at as low a dose as 10 mg/kg led to the development
of neurologic disorder in one of six rats. Thus, the low
dose of 5 mg/kg was thought to be the upper limit for the
therapeutic use of this drug. The effects of a low dose of
OPC-31260, on the other hand, were slow and weak, and
a gradual decrease of serum sodium level was noted after
it reached a maximum (on day two of the treatment). The
significant effects on urinary osmolality and urine volume
were also transient. In addition, although electrolytes and
urea accumulation in renal medulla decreased transiently
three hours after the initial administration, it returned at
the end of observation period to the level before treat-
ment. These results indicate the therapeutic limitations
of the treatment with OPC-31260 alone for SIADH. Al-
though the therapeutic efficacy and the safety of OPC-
31260 have been reported in SIADH patients [27, 38],
there are some conditional differences between clinical
trials and our present experimental models. First, the clin-
ical trials showed the effects of a single administration
of this drug within a short observation period, and thus,
the influence of long-term OPC-31260 treatment remains
to be determined, as was demonstrated with conivaptan,
a nonpeptide V1A and V2 receptor antagonist [39]. Sec-
ond, our experimental models underwent extremely low-
serum sodium, whereas SIADH patients in the clinical
trials demonstrated higher serum sodium. Thus, large al-
teration in serum sodium might lead to the potential brain
myelinolysis in our experimental models.
To assess the mechanisms underlying the therapeu-
tic limitations of OPC-31260, we examined AQP2 and
rBSC1 expression before and after OPC-31260 treatment
(Fig. 10). OPC-31260 markedly reduced both AQP2 and
rBSC1 protein expression three hours after the initial ad-
ministration, similar to the finding of Fujita et al that
AQP2 expression was reduced three hours after OPC-
31260 administration [7]. The expression, however, re-
covered within 24 hours to almost the same extent as
that before the treatment, and was further intensified on
days three and seven in spite of continuous treatment
with OPC-31260. These changes were consistent with the
transient increase of hypotonic urine during the 24-hour
period after the initial administration. These results sug-
gest that OPC-31260 shows therapeutic effects soon after
administration, but the blockade of the AVP V2 receptor
may discontinue the physiologic reactions to continuous
AVP stimulus, resulting in the dissipation of vasopressin
escape. The reelevation of rBSC1 and AQP2 expression
is therefore thought to be induced by the competitive
effects of excess dDAVP. Therefore, AVP V2 receptor
antagonists, such as OPC-31260, might limit their own
therapeutic effects in the SIADH rats by diminishing the
physical adaptation by vasopressin escape. On the other
hand, the administration of a higher dose that completely
blocks AVP stimulus may induce severe systemic toxicity.
After confirming the therapeutic limitations of the
AVP V2 receptor blocker for the treatment of SIADH,
we investigated other possible treatment regimens based
on the expressional alteration of rBSC1. Although the
increased level of rBSC1 expression by dDAVP infu-
sion was decreased due to vasopressin escape, its ex-
pression under the vasopressin escape condition was still
higher than that under the basal condition, indicating
that the enhanced sodium transport through this trans-
porter resulted in excessive water reabsorption, leading
to the maintenance of hyponatremia in the SIADH rats.
Thus, we attempted to reduce this sodium transport by
administering furosemide, a loop diuretic. The clinical
usefulness of furosemide in SIADH patients has been
demonstrated by the amelioration of hyponatremic
symptoms without causing any significant side effects
[28]. In most cases, however, possibly due to the negative
sodium balance during the treatment [28], the patients
had compensatory salt intake. In the present study, the
treatment with furosemide without changing dietary salt
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intake elevated serum sodium level in a dose-dependent
manner, although the elevation was slower and smaller
than that of a low dose of OPC-31260. Neither toxic ef-
fects nor disruption of sodium balance was noted even
when a high dose of furosemide (100 mg/kg) was admin-
istered, indicating the beneficial effects of this treatment
on the SIADH rats. As the functional inhibition of rBSC1
by furosemide is considered to have increased sodium
delivery to the distal convoluted tubules, compensatory
sodium reabsorption through the thiazide-sensitive co-
transporter (TSC) and the epithelial sodium channel
(ENaC) is thought to be induced in the distal convoluted
tubules and the cortical collecting ducts [40, 41]. This
adaptation may work adequately in furosemide treat-
ment of SIADH.
Finally, we designed a combination therapy using a low
dose of OPC-31260 and furosemide, expecting the com-
pensational effects of furosemide on the possible discon-
tinuation of vasopressin escape by OPC-31260 as well as
the additive therapeutic effects. The results demonstrated
the presence of the additive effect on serum sodium ele-
vation at both doses of furosemide, 30 and 100 mg/kg, al-
though they were extremely high doses. Furthermore, the
highly elevated serum sodium level mainly by OPC-31260
treatment was well maintained thereafter by administer-
ing a high dose of furosemide (100 mg/kg). We measured
the accumulated levels of sodium and urea in the renal
medulla of rats subjected to the combination therapy
(Fig. 6), and demonstrated that medullary sodium ac-
cumulation was significantly reduced by 100 mg/kg
furosemide. Therefore, in the combination therapy, the
acute reduction of both AQP2 and rBSC1 protein ex-
pression by a low dose of OPC-31260 leads to a rapid
and marked elevation of serum sodium levels in the short
term, after which furosemide may work to conserve the
elevated serum sodium level by inhibiting the countercur-
rent multiplier enhanced by the reappearance of rBSC1
and AQP2.
Since the original report of SIADH by Bartter and
Schwartz [4], SIADH has been described in an increas-
ing number of clinical settings, such as malignancies, pul-
monary diseases, central nervous system disorders, and
administration of certain drugs. Excessive AVP stimuli
underlie the development of SIADH in those diseases in
specific conditions, and therefore, the treatment involves
the exclusion of such AVP stimuli by inducing the remis-
sion of primary diseases or the cessation of medication.
In most cases, however, such complete treatment is dif-
ficult, and fluid restriction is the mainstay of the treat-
ment for SIADH patients. However, the clinical effects
of fluid restriction have been limited, in part, by the poor
compliance of the patients. Therefore, therapeutic med-
ication, if any, may help SIADH patients improve their
quality of life. The present study suggests that the com-
bination of a low dose of an AVP V2 receptor antago-
nist and furosemide ameliorates hyponatremia in SIADH
patients.
CONCLUSION
We have demonstrated the involvement of the expres-
sional alteration of rBSC1 in both the onset of SIADH
and the subsequent vasopressin escape. We have also
demonstrated the therapeutic limitations of the AVP V2
receptor antagonist, as the V2 receptor antagonist limits
its own therapeutic effects possibly by discontinuing the
physiologic reactions of vasopressin escape. Our present
study on therapeutic intervention suggests that the com-
bination of a low dose of a V2 receptor antagonist and a
loop diuretic most effectively ameliorates hyponatremia
in SIADH patients.
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